Observational studyWorld journal of gastroenterology2025

Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in inflammatory bowel disease.

Justin Kritzinger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.